Good morning, and welcome to HealthStream's fourth quarter 2021 earnings conference call. At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for question and answers after the presentation. I will now turn the conference over to Mollie Condra, Vice President, Investor Relations and Communications. Please go ahead, Ms. Condra.
Thank you, and good morning. Thank you for joining us today to discuss our fourth quarter and full year 2021 results. Also at the conference call with me are Robert A. Frist Jr., CEO and Chairman of HealthStream, and Scott A. Roberts, CFO and Senior Vice President. I would also like to remind you that this conference call may contain forward-looking statements regarding future events and future performance of HealthStream that could involve risk and uncertainties that could cause the actual results to differ materially from those projected in the forward-looking statements. Information concerning these risks and other factors that could cause the results to differ materially from those forward-looking statements are contained in the company's filings with the SEC, including Forms 10-K, 10-Q, and our earnings release. Additionally, we may reference measures such as adjusted EBITDA, which is a non-GAAP financial measure.
A table providing supplemental information on adjusted EBITDA and reconciling to net income attributable to HealthStream is included in the earnings release that we issued yesterday and may refer to in this call. We had an exciting event at the end of the fourth quarter that we highlighted as our first bullet in the earnings release. The bullet stated: Our CEO contributed $2.4 million of his personally owned HealthStream stock to the company in order to facilitate the grant of shares of common stock to over 1,000 employees under our 2016 Omnibus Incentive Plan, which resulted in a corresponding $2.4 million charge for stock-based compensation and related expense in the fourth quarter.
Given that event, I'd like to extend a special welcome in this conference call to our employees, many of whom are new shareholders of the company, and they might be listening to one of our quarterly conference calls for the first time. It's exciting to see so many of our employees realize the opportunity to become an owner of the company that they've helped to build. With that start, I'll turn the call over to Bobby Frist.
Thank you, Mollie. Good morning, everyone. Welcome to our fourth quarter and full year 2021 earnings call. We've got a lot to cover, so we'll jump right in. 2021 was a year of record-setting revenue and record adjusted EBITDA for our company. Our employees achieved these records despite the challenges of the pandemic. Through it all, we stayed focused on being the platform where partners and customers turn to empower the healthcare workforce. Throughout the pandemic, that focus has continued to pay off for our company, our customers, and our partners. As we get into more detail about last year's results and this year's guidance, you will see why I'm more confident than ever that it'll continue to pay off. Let's look at a quick recap of financial and operating results before our CFO, Scotty Roberts, takes us deeper into the numbers.
We ended 2021 with revenues up 5% and adjusted EBITDA up 15%. We ended the year with over 5 million hStream subscriptions contracted. We also completed two acquisitions. We're awarded two patents, and our innovative products were recognized with four prestigious awards. In this call, we'll elaborate further on how these and other developments lay the groundwork for what we believe will generate shareholder value. Before we do that, we need to take note of the context in which we're operating. By most accounts, the pandemic in the United States appears to be in retreat. Even with the last Omicron spike, COVID-19 hospitalizations have decreased 18% nationwide over the last two weeks. On Thursday, a White House official said the U.S. is getting closer to a time when COVID-19 is no longer a crisis.
We are hopeful that that time arrives soon, as those most greatly impacted tend to be the frontline workers in the healthcare organizations that we serve. The long-run impact is still being determined, particularly among the healthcare workforce. Onboarding, retaining, and engaging the healthcare workforce has never been more important to healthcare organizations. Our job at HealthStream is to help them achieve these goals, and I believe we are well-positioned to do just that through both our established products and through new innovative products like Jane that we've introduced recently. Like many companies, we have adopted a hybrid workplace approach where most employees primarily work remotely. Our employees have proven to be effective, and they've embraced this new, more flexible work model. HealthStream, like most companies, has experienced high turnover, but we've also experienced enormous hiring levels at the same time.
The net effect for the full year 2021 is that our head count has increased, just not as much as we would like. Fortunately, we are attracting and hiring fantastic talent, which speaks highly to the strong corporate culture our employees have built. It's also encouraging that our net new hire number was up considerably in the fourth quarter versus any one of the first three quarters of 2021. Finally, building on our record-setting performance in 2021, we are pleased that our financial guidance for full year 2022 reflects continued investments and solid financial growth. At this time, Scotty Roberts will provide a more detailed discussion of the financial metrics for the fourth quarter and the full year of 2021, along with further comments about how we view our financial outlook for 2022. I'll turn it over to Scotty.
Thanks, Bobby. I'll jump right in and start with an overview of our financial results and then go over guidance expectations for 2022. First, as mentioned earlier, for the third time over the past seven years, our CEO gifted his personal stock to the company, which was used to facilitate a stock grant to over 1,000 employees. This grant excluded executives and vice presidents of the company. The financial impact of the stock grant was $2.25 million of non-cash compensation and $185,000 of employer taxes and administrative costs. Despite being fully funded personally by our CEO, GAAP requires this transaction to be accounted for as a compensation expense of the company, which negatively impacted our financial results for the quarter by reducing operating income by $2.4 million, net income by $1.9 million, EPS by $0.06 per share, and adjusted EBITDA by $185,000.
Please let me take a quick aside to put this into context. When I talk about Bobby's generous contribution negatively impacting our financial results, I wanna be clear that I'm only talking about the accounting treatment. Bobby donated his own personal shares in an amount that offset the shares and related expenses that I've characterized as having a negative impact. To be sure, we believe Bobby's contribution had a positive impact, both to shareholders and to employees. Shareholders benefit from having a CEO personally contribute his own stock in order to compensate, engage, and incentivize employees who are now owners and tied to the outcome of their company. Employees obviously benefit by becoming shareholders themselves, who will now enjoy the value of what they work so hard to create. Okay, now back to our financial results.
For the fourth quarter, revenues were $64.3 million, which is up 4% over last year, and includes a $0.4 million reduction associated with deferred revenue write-downs. We experienced an operating loss of $0.5 million, a net loss of $0.4 million, and a net loss per share of $0.01. These financial results were impacted by the stock grant accounting treatment that I just mentioned, while adjusted EBITDA improved to $12 million, which is up 12%. Workforce Solutions revenues were $50.9 million and were up 2.4%, and revenues from Provider Solutions were $13.5 million and were up 10.8%. The combination of organic growth and revenues from acquisitions more than offset a $6.6 million decline from the legacy resuscitation products.
Excluding the legacy resuscitation revenues, consolidated revenue growth was 16.6%, which was comprised of 6.2% organic and 10.4% from acquisitions. Gross margin was 64.3% compared to 63.2% last year. The impact of the employee stock grant accounting treatment reduced gross margin by approximately $0.9 million or 140 basis points. Adjusting for the impact of the stock grant accounting treatment, gross margin would have been 65.7%. Operating expenses, excluding cost of revenues, were up 10% or $3.9 million over last year. Approximately $1.5 million of this increase is from the employee stock grant accounting treatment. Another $1.2 million is from increased depreciation and amortization, and the remainder is from other expenses, including those associated with acquisitions.
Additionally, we experienced higher bad debt charges in the quarter of approximately $600,000, most of which were related to a customer bankruptcy. Adjusted EBITDA was $12 million, increasing by 12% over last year, and adjusted EBITDA margin was 18.7% compared to 17.4% last year. We ended the year with cash and investment balances at $51.9 million, which is down by $8.7 million since last quarter. During fourth quarter, we deployed $4 million of cash to fund the Rievent acquisition and used $5.1 million for share repurchases. DSO for the quarter was strong, improving to 41- days compared to 50- days last year. For the full year, our cash flows from operations improved by 18% to $42.4 million compared to $35.9 million last year.
Free cash flows were down slightly, coming in at $17 million compared to $17.4 million last year, and this reduction was impacted by higher capital expenditure payments during the year of six and a half million. Our capital expenditures incurred, which primarily consist of capitalized software development, were $6.6 million for the quarter and $23.4 million for the full year. On November 30, we announced the authorization of a share repurchase program of up to $20 million of our outstanding common stock. As of December 31, we had acquired shares valued at $5.1 million under the program. The repurchase program will terminate on the earlier of November 29, 2022, or when the maximum dollar amount under the program has been expended.
We may suspend or discontinue making purchases under the program at any time, and we plan to closely monitor factors such as market conditions, our liquidity, working capital, and cash flow projections when making decisions regarding the program. On December first, we completed the acquisition of Rievent Technologies for $4 million in cash. This acquisition did not have a material effect on the quarter's financial results. Now, reflecting on the full year, we achieved several meaningful milestones, including record revenues of $256.7 million and record adjusted EBITDA of $52.7 million. We also completed two acquisitions, ComplyALIGN in January and Rievent in December. We ended the year with over 5 million contracted subscriptions to hStream. On behalf of myself and fellow leaders of the company, I wanna say thank you to all of our employees who made this such a successful year.
Now, moving on to guidance expectations for 2022. Consolidated revenues are forecasted to range between $267.5 million and $273 million. Workforce Solutions revenues are forecasted to range between $214.5 million and $218 million. Provider Solutions revenues are forecasted to range between $53 million and $55 million. Adjusted EBITDA is forecasted to range between $50 million and $53.5 million, and we expect capital expenditures to range between $26 million and $29 million. While we expect another solid year in 2022, the pandemic is not over and our business may continue to experience the same obstacles we've worked through the past two years.
During the second half of 2021, the pandemic continued to present challenges for our customers who faced the Delta and Omicron variants, coupled with labor shortages, fatigued staff, and rising costs of temporary labor. These factors resulted in delayed purchasing decisions by customers and had a direct effect on our sales bookings, which fell short of our expectations. The shortfall in bookings is reflected in our guidance and projected growth rates. We expect the labor market will continue to be competitive again this year. In 2021, we had higher than normal employee turnover rates while also hiring more employees than in our history. Our total headcount increased by 3% during 2021, and most of this growth happened in the fourth quarter. Managing our employee retention rates while filling open positions are important to the execution of our objectives for this year.
Our forecast assumes staffing levels to increase between 5% and 7% to support investments in sales, marketing, and product development. We also assume that certain expenses, such as travel and trade shows, will gradually be reintroduced into our cost structure. Both of these were curtailed over the past two years, and in 2019, they approximated $5.5 million. While we don't anticipate spending at this level in 2022, these costs are expected to be significantly higher than they were in 2021. Another area we are increasing investment is in cloud hosting. Our technology infrastructure has been steadily migrating to the cloud, which increases our operating expenses, but is expected to reduce our capital needs for servers and co-location services over time.
Our planned investments back into the business are essential to our strategy of becoming a single platform company that's capable of integrating proprietary and third-party applications in a way that increases their value to and adoption by the healthcare market. Our gross margin profile improved in 2021 and approximated 64.5%. We expect to maintain gross margin in the mid-60% range for 2022. We have a long history of using M&A to drive growth and expand our product portfolio. In 2020, we acquired three companies that currently comprise our scheduling and capacity management application suite. We bookended last year with an acquisition to start the year in January and one to end the year in December.
Regardless of the size of acquisition, we believe that sourcing and completing acquisitions is a core competency of our company, and our M&A program has an established playbook for doing just that. We plan to continue to pursue growth opportunities through M&A, and just as we always have, we will continue to be disciplined in order to find the right strategic fit at an appropriate valuation that we believe will create returns. While we maintain an active M&A opportunity pipeline, our guidance does not include the impact of any acquisitions that we may complete during 2022. Finally, our capital deployment for 2022 will be focused on supporting future growth initiatives and improving shareholder value.
Our capital expenditures are expected to increase over last year, and incremental investments will be focused on the continued development of our hStream platform and ecosystem, as well as a number of core applications. In addition, $15 million remains available under our share repurchase program. We anticipate funding these capital needs through our existing cash balances, cash flows from operations and if necessary, our revolving credit facility. Thanks for your time this morning. Bobby, I'll turn the call back over to you.
Thank you, Scotty. We've got several business updates I'd like to provide, and we'll look at that in just a second. First, I wanna remind you how we're talking about our business today because it's changing. We've come a long way since pioneering internet-based training to fulfill governance, risk, and compliance needs in healthcare. We obviously still do that, but how we do it, along with many other things we do now, continues to evolve. As you know, we've been developing a platform strategy as the foundation for our entire enterprise. We call the technology platform hStream, and increasingly, it will enable the applications and the platform strategy. We have three primary application suites. They are learning and development, credentialing and privileging, and scheduling and capacity management. Let's walk through some updates on hStream and each of these three application suites. First, hStream.
We added about 118,000 hStream subscriptions in the fourth quarter, bringing our total to 5.04 million subscriptions. This represents an increase of 21% over the same period last year. The growth in subscriptions is encouraging, and another thing I want to highlight is the growing opportunity of the hStream ecosystem. On our last call, I described some of the innovative new technologies of our hStream platform, including how the hStream ID enables management of a person's license data across multiple applications. Today, I wanna talk about another critical element of our hStream platform strategy, the ecosystem itself. In general, I think of an ecosystem as a community of participants that interact with one another and their environment in order to prosper and grow.
In terms of the hStream ecosystem, the participants are our partners and our customers, and our environment is the healthcare workforce space. How we interact together to ensure growth is our platform strategy at work. Admittedly, that's a little abstract, so let's take hStream certified partners as a specific ecosystem example. What we have found is that some partners prefer to sell their products directly to customers, but their ability to do so successfully is dependent on the integration with our technology platform. We developed a certification program that allows partners who meet defined standards to achieve hStream certification. If a customer sees that a product is hStream certified, they know that product can be delivered through our hStream platform.
The hStream certification helps drive sales of the partner's product, provides greater choice of solutions to our customers, and results in a revenue share to us and added utilization of our platform. Through this example, you can start to see how the self-reinforcing interplay between ecosystem participants benefits everyone involved and makes the ecosystem stronger. Now I'd like to provide some updates with regard to our three application suites. Let's start with learning and development, our most well-respected application suite. In fact, the company's origins trace back to improving learning and development through technology, which is what these applications focus on today.
The past two years have been characterized by a great deal of innovation across this area, including the release of our patented AI-driven clinical competency application known as Jane, the establishment of a new industry standard in resuscitation certification with the American Red Cross Resuscitation Suite, and the combination of our ComplyQ and SafetyQ solutions to form what we believe is the most dynamic compliance and safety solution in the market today. We continue to see momentum with the Jane solution, which officially launched in 2019. As a reminder, Jane represents a patented intelligence that accelerates and personalizes the competency development of nurses. We shared in the second quarter of 2021 that we saw an average of one sale each week throughout 2020, or a total of 52 new accounts formed.
Throughout 2021, that increased to over 1.5 sales each week, with our first large system customer purchasing in early 2021. Throughout the course of the pandemic, we've seen customer use of Jane accelerate. One customer said, "Jane allowed us to quickly evaluate and prepare nurses for transition into new care areas in response to COVID." Given the amount of cross-training and upskilling our customers have had to undertake across their nursing population, our Jane solution has really made that much easier with its ability to personalize development. This allows our customers to more quickly and easily identify competency gaps and to develop directly to those gaps, decreasing the amount of time nurses spend away from the bedside. To round out learning and development updates for the quarter, I'd like to focus on one of our resuscitation offerings.
Since the launch of the American Red Cross Suite in the first quarter of 2019, we have sold to healthcare facilities of all types and sizes from across the continuum of care across all 50 states, including some of the industry's largest acute care healthcare systems and organizations. As of December 31, 2021, approximately 400,000 certifications from the American Red Cross have been earned through the HealthStream network. In addition, we've deployed over 7,600 Innosonian Brayden Pro manikins into the market in less than three years. These are manikins that customers use to demonstrate the skills component of their resuscitation training. We believe it is remarkable that solutions that did not exist in the market just three years ago have gained such widespread adoption.
We are also pleased that our customers continue to rate the implementation process for the American Red Cross Resuscitation Suite very highly, providing an average score of 4.7 out of five during the fourth quarter. We look forward to continuing to delight our customers by bringing even wider array of resuscitation offerings to the market this year. Three years ago, we announced the launch of CredentialStream, our new SaaS-based application for managing the full spectrum of credentialing, privileging, and enrollment needs in healthcare organizations. For the full year of 2021, 167 customer accounts contracted for CredentialStream, averaging about 3.2 new contracts per week. These accounts represent a mix of new customers and existing customers who chose to migrate from our legacy credentialing and privileging platforms to the new CredentialStream application suite.
Some of the customers we contracted in the fourth quarter include large health systems like Banner Health, Southeast Health, and Paramount Health Options. We are excited to be gaining adoption of this best-in-class solution our team built after taking the time to understand and improve on the best parts of the legacy solutions we acquired through M&A. While we are still early in the journey on our scheduling and capacity management solution, we are pleased with the progress on several fronts. We currently have about 400 customers across scheduling and capacity management application suite, which reflects good retention of the customers we acquired and includes the addition of 30 new customers during the course of 2021.
Filling open sales positions was a challenge during 2021, so we are encouraged to see that this sales team began 2022 with almost all the open positions filled, effectively doubling the sales organization as we had planned. Our product strategy and roadmap for scheduling and capacity management continues to take shape. For example, NurseGrid Mobile continues to be the number one rated app for nurses with a 4.9 star rating and more than 70,000 reviews. That's up from 40,000 reviews at the time of acquisition. That's all occurring in Apple App Store. Today, over one in 10 nurses are active users on the NurseGrid Mobile app, with 365,000 monthly active users, up 105,000 since the acquisition in March 2020.
46% of those nurses log in every day to manage and share their schedules, create social connections with their colleagues and peers, swap shifts, and volunteer to fill open shifts. In 2021, NurseGrid Mobile facilitated over 32,000 shift swaps and were used to fill 27,000 open shifts, demonstrating its potential for addressing the nurse staffing shortage crisis impacting healthcare organizations. As you can tell, we believe NurseGrid can provide and prove to be a real differentiator in the market for our scheduling and capacity management application suite. Now, a few business updates as we wrap up and then head into questions. In January of this year, we announced the addition of Terry Rappuhn to our board of directors, where she is serving as a member of our audit committee.
She has served on six public companies and as audit committee member and as a financial expert for all six boards, while also serving as the CFO of Coram Healthcare Corporation from 1999 to 2001. Additionally, she brings cybersecurity governance expertise to the board as she holds a CERT cybersecurity certificate in cybersecurity oversight from the National Association of Corporate Directors and Carnegie Mellon University. We are pleased that she has joined our board and expect that she'll add a valuable perspective to our discussions as she advises our company. Friday, March 4 is National Employee Appreciation Day, and I want to start this early by thanking all of our employees for their hard work, perseverance, and dedication they've shown over the last year.
It's been almost two years, in fact, that we've all been working from home, and our employees have made this transition seamless in terms of outstanding service to our customers while also growing the company. I'm proud of their achievements and honored to be their leader. At this time, I'd like to turn it over for questions from the investor community.
As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from the line of Matthew Hewitt from Craig-Hallum Capital Group. Your line is now open.
Good morning. Thank you for taking the questions and for all the details and the prepared remarks. Maybe first up, as we start to exit COVID, hopefully, you know, the headlines have talked about the stress that is put on hospitals and healthcare providers from an employment standpoint. Do you think that this is something that will be fixed or resolved relatively quickly this year, so you should see a nice pop from a bookings perspective right away? Or do you think that this is going to take some time and therefore the year might be more back half-weighted?
I think there's a lot of ways to answer that question. If you're the CEO of a hospital, I think the stress remains in your workforce. It's almost post-traumatic to what this workforce has been through, and you're still dealing with burnout and fatigue. I think if you think of it emotionally, the operators have a lot to deal with to try to recruit and retain and develop employees. In that regard, I think that's gonna persist for a while, and so I don't think that'll be over. On the other side, the operations of hospitals and large health systems are having to find a way to operate. I would say they've gotten better, both systemically, operationally, logistically at operating during these types of crisis.
Their workforce challenges persist, but I think they're finding ways to get on with the business of healthcare. That's really a testament to their strength and their commitments to doing that. I think we'll still see pockets that are gonna be slower. There are different types of issues, like do you wanna take on new products when there's so much stress in your workforce? We did see a little of that in the fourth quarter, where we effectively felt really confident we were gonna win the business. In fact, the chief medical officers would say, you know, "This is something that we'd like to do.
It's just not now the time to implement something that changes the work environment at all." It did cost us some business, where kind of, in that case, incumbency was favored just because of change management. I think the impact will be lingering. We think we've factored that into our forecast of the 4%-6% revenue growth. We think that we've handled how we think our sales will recover through the year. As you know, this year's results are particularly heavily dependent on last year's selling results, where we did see that negative impact. The first, say, quarter or two of this year are what will determine the in-year impact on our forecast.
We'll have a lingering effect, which again is already factored into the growth-oriented guidance that we were able to give. It would have been nicer if the growth rate was a little higher. We think we've accommodated the challenges we'll face in selling.
That, that's really helpful. Thank you. I guess maybe a follow-up to that. For the customers that did defer decisions, stayed with incumbents, whatnot, is that something where they could come back here in Q1 or in Q2, or are you typically waiting till the next renewal, which could be a year to three years out? Maybe just walk us through that process.
Well, yeah, a lot of things there. I mean, that one that I specifically referenced where they just said, "You know what? We just don't want to impose change right now during the fourth quarter on our workforce," for one solution. They actually seemed very emotionally committed to the change, meaning they preferred our product. I don't think we really lost the sale, we deferred it. The second thing was, because they felt a little bit guilty about that deferral, in other words, they really had indicated they preferred our products and were ready to move, or were excited to try them, but just wasn't the time, they actually committed to reviewing other products from our company that might be able to work in more easily than the one we had shown. I feel our customer relationships are strong.
We've been flexible with our customers throughout the pandemic. We've tried to offer assistance to them where we could with some forms of free training and resource access. I think eventually that will pay back. Like in that one case that I gave, I really think they'll actually probably buy a different product from us early in the year and keep the one that was deferred on the schedule for the next renewal.
That's really helpful. Thank you. Maybe one last one, and then I'll hop back in the queue. Thank you for the update on Jane. I'm curious, how many of your customers today are utilizing Jane? Obviously, it sounds like you've seen an acceleration in adoption of that platform, but or that application, but where is that currently, from your installed base?
It's a great question. I was looking at the number of contracts, but I have to look at it from a market share perspective, which I don't have handy. Maybe next earnings call. Our team right now will take some notes, and we'll try to come up with kind of a market share assessment for you. I refer to the number of contracts, but I don't have right at the tip of my fingers here, because if there's a large health system, there's different market share implications. Let's put that on the slate for next quarter.
Sounds like a plan. All right, thank you.
You could see the contracting velocity. The key of the call was the contracting velocity went up about 60% from kind of one a week to 1.6 a week, which is good.
Thank you. Our next question comes from the line of Ryan Daniels from William Blair. Your line is now open.
Hey, guys. This is Jack Senft on for Ryan Daniels. Thank you for taking the question, and congrats on the quarter. I know in previous quarters you were targeting, I think it was 65% gross margins over the long term. I'm just kind of curious if you can provide any color on how we should think about what is assumed to be 2022 guidance for gross margin. You know, if there's anything you need to call out in terms of investment integration, any additional information or color that you guys have on that would be appreciated. Thanks.
Thanks. I'll take it and then let Scotty add some color to it. I think that we have changed the gross margin profile and should be able to maintain that mid-60%, like 65% gross margin throughout the year. We feel really good that there's kind of a fundamental shift based on our product mix. The new products we're introducing, frankly, have higher gross margins. We hope for, you know, over a long period of time, improving gross margins even from here. I think throughout 2022, it's kind of safe to plan around the 65% gross margin level. Scott, do you want to add anything to that?
No, I think you got it spot on, Bobby. I think, you know, that's our guidance is mid-60% range, and the factors Bobby just mentioned are the ones that I would have stated as well.
Thank you. Great. Thanks, guys. Just for a quick follow-up on guidance too. You mentioned the shortfall in bookings in your prepared remarks. I'm just kind of curious how this impacts the visibility of your guidance or, maybe if the shortfall is due to more elevated levels of competition given the, you know, kind of importance of workforce management. I guess anything you can provide here would also be great. Thanks.
Sure. I think as far as visibility, I mean, the contracts that came in, we didn't get quite as many as we'd hoped, and so the forward revenue from the ones we did get are in our forecast, and we've kind of adjusted to what we think is our sales rate, which is therefore also in the forecast. We think we've accommodated the conditions we faced last year in our forward guidance pretty thoughtfully. I think both conditions have been met, meaning that last year's shorter than expected results are already in the guidance on a forward basis. Then the ongoing impact of slightly lower sales, although our staffing levels are returning, that was one negative contributor last year. Now our staffing levels are returning, which is good, particularly in the sales organization.
We think we factored both carefully into the guidance we just gave. I think you already signed off on that, so we just open it up for other questions.
Thank you. Our next question comes from the line of Vincent Colicchio from Barrington Research. Your line is now open.
Yeah. Yeah. Bobby, you mentioned that you had a good hiring quarter in Q4 versus the prior three. Did you increase wage inflation, wage increases to do that versus the last quarter?
So far, not so much. Although I think as we move into this year, we're trying to plan thoughtfully about how we'll increase. What we've been able to do is find eager and excited people to backfill or a lot of internal promotions. If a manager of a six person department left, we've been able to find an internal candidate where it would be a promotion and a pay raise for them to move up. I think what's happened is some upward mobility within our organization resulting in higher pay for those individuals, while some of the individuals that left the company maybe found higher responsibility and higher pay by leaving. The net impact so far on us has been fairly conservative.
I think we're trying to factor into our budget in this year a little bit more pay increases in certain areas where that'll be necessary to get what we need done. So far, we've been able to hire people or promote from within to fulfill them. The result has been fantastic, like 167 promotions inside of our company, people taking on more responsibility for more pay, taking the position of their, say, prior boss who, you know, made more than them. They again got higher pay, but it was kind of budget neutral for us.
Can you give us some color on the resuscitation suites you plan to add in 2022?
We've got a robust roadmap there. Over time, we've added products like the S.T.A.B.L.E. product, which you may have heard us talk about in the past. We have a robust pipeline of innovations with the Red Cross that is scheduled. Then a few other categories I can't talk about, but watch for that. Just kind of wanted to tease out to watch for some additional innovations in resuscitation. The theme would be to round out and complement the basic packages, which are ACLS, BLS, and PALS, to hit more specific practice areas and more types of scenarios for learning. Maybe even broaden the definition of what life-saving technologies and life-saving methodologies are.
This resuscitation isn't the only thing that causes, you know, codes and so there are other ways to address the problem. Sorry for the vagueness, but we've already laid out a decent portfolio with S.T.A.B.L.E., American Red Cross, and we expect innovations in both of those areas.
Scotty, I'm not sure that I got the right number. Excluding the legacy resuscitation revenue, organic growth was that 2.8%?
On a consolidated basis, once you back out the $6.6 million from legacy that was down year-over-year, organic grew by 6.2% and $10.4 million from acquisitions for a total of $16.6 million.
Organic 6.2% increase for the year, is that right?
That's for the quarter. Sorry.
For the quarter.
Last full year. Yep.
Yeah, I was more interested in the quarter anyway. Okay. 6.2. Thanks for that. Nice job in the quarter, guys. Thank you.
Thanks.
Thanks, man.
Our next question comes from the line of Richard Close from Canaccord Genuity. Your line is now open.
Great. Thanks for the questions here. Bobby, I was wondering if you could give an example of the Certified Partners program on HealthStream and maybe how we should think about that as a revenue driver for the company longer term, and I would assume it's much higher margin business for you.
Thanks, Richard. Yeah, it actually is. A couple of exciting things there. We have the number of partnerships and revenues have doubled. Largely, remember. A good example might be our relationship with Press Ganey, where Press Ganey uses our network to deliver education and training and development programming through our network, but they sell it as bundled with their own services under the Press Ganey contract. That's a good example of a multi-year agreement in place where we're effectively the distribution partner, and it allows our customers, the hospitals to manage the Press Ganey content consistent with how they manage, you know, 75 other vendors' content. There's benefits for the customer, meaning the hospital.
It benefits Press Ganey because allows us to manage distribution and directing their content within our network to where they want it directed. We've created a model where it's easy for them to achieve the contracts, they recognize the top-line revenue, and they effectively pay us a technology and distribution fee to assist in the targeting of their content into our ecosystem. That's an example, the Press Ganey relationship, and those type of partnerships are growing. Often we use it to introduce more content in a given area where there may already exist competition inside of our network. In the clinical skills area, we've done that with a few partners where they sell their own through their brand, but they fulfill it and distribute it through our network.
Yes, it is high gross margin revenue because it's essentially a technology and access fee for an existing network, and the revenue streams are growing. We'll probably break out some of that in the future, but we consider that attributable to the capabilities of our growing platform and ecosystem.
Okay, helpful. On Provider Solutions, you know, I guess the guidance here is for, you know, 4.5%-7% type of growth in 2022. Based on the comments of three sales per week, I would have thought that maybe growth would have accelerated. Is there a reason we're not seeing that sort of flow through those higher sales per week?
Yeah, it's interesting on the revenue side. When you land a big system, it takes a long time to implement and get it, you know, get to the revenue recognition or the change in revenue recognition. If you take a big system like a Banner Health or a Providence, which is just a massive multi-year project, it takes time for that revenue to roll in and become kind of solid base. On the other hand, we have light versions of our products that we sell at a high velocity, but they're very small and much simpler to implement, and they handle the process for a group of physicians or a small clinic or a smaller organization.
The number of transactions may be reflective of a mixture of the very small, quick to implement and faster to revenue. The overall growth rate, though, may be impacted by the length of time it takes to roll out some of the larger enterprise wins.
Okay, that's helpful. Then just going back over the 2021 bookings, and I appreciate that, you know, the commentary that, you know, it was below, but factored in, into guidance. Giving you good visibility there. Can you just remind us maybe the progression of bookings throughout 2021 in terms of, you know, versus your initial expectations, like how the first quarter, second quarter, third quarter, sort of, compared to the fourth quarter?
Yeah. I mean, just in general, the second and fourth quarters are generally expected to be higher than the first and third quarter. If you think of a progression throughout the year, I'd say the second quarter is generally a higher period of closing contracts than the fourth quarter. Generally, of those two, the second and the fourth, the fourth quarter is the largest. Obviously, you know, early fourth quarter deals that can get implemented by, you know, January, February, or March of the next year have an impact on the revenue of next year. I'd say our biggest relative miss, because the way we budget is, you know, aligned with those patterns on a relative and maybe even absolute basis, the largest miss was the fourth quarter.
That said, it was a good quarter. It's just, again, relative to expectations, it's usually the biggest. It was still, I believe, the biggest. It just, you know, we wanted more. As you play that out, you know, by January, we've closed out all those contracts. We know how to project the revenue from them very precisely, and we can layer that into our multiyear forecast and then come up with essentially our budget and our guidance. I would say that our biggest expectations are generally in the fourth quarter.
Okay. My final question is, I know Scotty talked about the contribution from acquisitions. I think it was 10% or so in the fourth quarter. Can you know, talk maybe at a higher level in terms of the 2020 acquisitions and the two January and then December of last year, in terms of, you know, just remind us like how you view the growth, longer term growth profile, or growth opportunities with those acquisitions from a cross-sell or upsell perspective.
Sure, sure. That it takes time, but let's outline it a little bit. If you think about last year's kind of core acquisitions, they were more significant for us. They prepared us to enter into scheduling kind of a new, as we call it, a leg of the stool. Holistically, when we bought ANSOS, ShiftWizard, and NurseGrid, all in pretty rapid succession, those three have been formed into a new solution group or product family for scheduling and capacity management. I would say those three, therefore, are early stages of integration, technology investment, and we would think, you know, in the cycles of, say, 24-36- months to get real IRR return on a lot of those investments. Good momentum, as I talked about in some of the core applications like NurseGrid.
On the other hand, the prior four acquisitions that spread out over a longer period of time, but that created our credentialing and privileging enrollment solution set, I believe we're beginning to get what I'd call the early returns. You know, where we're getting the early IRR, almost calculable returns on the capital deployed, through the strength of the EBITDA of those programs, the migration of customers to the newly created platform, which has now been in the market two years. Wins like Banner Health and Providence Health & Services, major system commitments to the CredentialStream platform.
There, I'd say we're hitting that hitting stride on getting a return on those four acquisitions with probably over $140 million of investments over, well, over, if you leave out the first one, over a five year period, but if you take the first one into account, over a 10-year period. I think if you take credentialing, privileging, enrollment and think of it as hitting stride, meaning the replacement technology has been built, customers are migrating, we're selling the newer software only, and we're upgrading clients to it, then we expect to start to see returns now. We're starting to see that in the EBITDA contributions and generally the growth rates, as you can tell from the forecast. We're excited about that. Scheduling capacity management, early stage.
You know, we've put together three things in the last 24- months, and we probably have another 24- months of investing.
What about the 2021 acquisitions?
Oh, yeah, they were just little tuck-ins that we're excited about. They add dimension to our ecosystem. For example, Rievent is an interesting little company that has figured out very unique workflows in the CME office at hospitals. It's kind of a unique dimension of education and training that we feel HealthStream should have a presence in. Our learning platform should handle about 80% of those needs, but this little company kind of tailored its software to the needs of something called the CME office. I think of it as kind of a niche workflow app that makes sure that we stay relevant to all the educational initiatives inside of a hospital.
It's a nice little tuck-in, you know, won't require major investments to overhaul the software, rounds out more of our education, training, and development platform capabilities. We're excited about that as a little tuck-in. Not terribly expensive, and nice value add to customers.
Okay. Thank you. Congratulations on closing 2021. Good luck this year.
Thank you.
Thank you. At this time, I am showing no further questions. I would like to turn the call back over to Robert A. Frist, Jr., CEO, for closing remarks.
Thank you to everyone. This concludes our earnings call. Look forward to the next report, and see you all soon. Thanks to our employees for a great year, and looking forward to this 2022.
This concludes today's conference call. Thank you for participating. You may now disconnect.